{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:25:25Z","timestamp":1769606725955,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04547-0","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T01:24:34Z","timestamp":1766453074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey"],"prefix":"10.1186","volume":"26","author":[{"given":"Sharmilee","family":"Gnanapavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarunya","family":"Arun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rushworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazanin R.","family":"Kondori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"4547_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"4547_CR2","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: A review. Am J Med. 2020;133(12):1380\u2013e902.","journal-title":"Am J Med"},{"issue":"7","key":"4547_CR3","doi-asserted-by":"publisher","first-page":"e230016","DOI":"10.57264\/cer-2023-0016","volume":"12","author":"IA Samjoo","year":"2023","unstructured":"Samjoo IA, Drudge C, Walsh S, Tiwari S, Brennan R, Boer I, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023;12(7):e230016.","journal-title":"J Comp Eff Res"},{"issue":"4","key":"4547_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"issue":"9","key":"4547_CR5","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, Ocampo A, Hatami F, \u010cuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147\u201361.","journal-title":"Brain"},{"key":"4547_CR6","doi-asserted-by":"publisher","first-page":"175628642412293","DOI":"10.1177\/17562864241229325","volume":"17","author":"O Hoffmann","year":"2024","unstructured":"Hoffmann O, Gold R, Meuth SG, Linker RA, Skripuletz T, Wiendl H, et al. Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making? Ther Adv Neurol Disord. 2024;17:17562864241229325.","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"4547_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653\u201370.","journal-title":"Lancet Neurol"},{"issue":"9","key":"4547_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of Relapse-Independent progression vs Relapse-Associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"issue":"5","key":"4547_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653\u201366.","journal-title":"Ann Neurol"},{"issue":"10","key":"4547_CR10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1177\/1352458521993066","volume":"28","author":"S Thebault","year":"2022","unstructured":"Thebault S, Bose G, Booth R, Freedman MS. Serum neurofilament light in MS: the first true blood-based biomarker? Mult Scler. 2022;28(10):1491\u20137.","journal-title":"Mult Scler"},{"issue":"Suppl 1","key":"4547_CR11","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5\u201348.","journal-title":"Mult Scler Relat Disord"},{"key":"4547_CR12","doi-asserted-by":"publisher","first-page":"991291","DOI":"10.3389\/fimmu.2022.991291","volume":"13","author":"B Van Wijmeersch","year":"2022","unstructured":"Van Wijmeersch B, Hartung HP, Vermersch P, Pugliatti M, Pozzilli C, Grigoriadis N, et al. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. Front Immunol. 2022;13:991291.","journal-title":"Front Immunol"},{"issue":"8","key":"4547_CR13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"4547_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458518765666","volume":"25","author":"N Siller","year":"2019","unstructured":"Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25(5):678\u201386.","journal-title":"Mult Scler"},{"issue":"5","key":"4547_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1352458512443092","volume":"18","author":"CE Teunissen","year":"2012","unstructured":"Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552\u20136.","journal-title":"Mult Scler"},{"issue":"10","key":"4547_CR16","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1093\/brain\/awab241","volume":"144","author":"S Bittner","year":"2021","unstructured":"Bittner S, Oh J, Havrdov\u00e1 EK, Tintor\u00e9 M, Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;144(10):2954\u201363.","journal-title":"Brain"},{"key":"4547_CR17","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J, et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 2024;101:104970.","journal-title":"EBioMedicine"},{"issue":"8","key":"4547_CR18","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141(8):2382\u201391.","journal-title":"Brain"},{"issue":"3","key":"4547_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli \u00d6, Maceski A, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246\u201357.","journal-title":"Lancet Neurol"},{"issue":"6","key":"4547_CR20","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857\u201370.","journal-title":"Ann Neurol"},{"issue":"10","key":"4547_CR21","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315.","journal-title":"Neurology"},{"key":"4547_CR22","doi-asserted-by":"publisher","first-page":"103535","DOI":"10.1016\/j.msard.2022.103535","volume":"59","author":"S Thebault","year":"2022","unstructured":"Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, et al. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022;59:103535.","journal-title":"Mult Scler Relat Disord"},{"key":"4547_CR23","doi-asserted-by":"publisher","unstructured":"Thebault S, Booth RA, Freedman MS. Blood Neurofilament Light Chain: The Neurologist\u2019s Troponin? Biomedicines. 2020;8(11):523. https:\/\/doi.org\/10.3390\/biomedicines8110523.","DOI":"10.3390\/biomedicines8110523"},{"key":"4547_CR24","doi-asserted-by":"publisher","first-page":"852563","DOI":"10.3389\/fimmu.2022.852563","volume":"13","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, et al. Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials. Front Immunol. 2022;13:852563.","journal-title":"Front Immunol"},{"key":"4547_CR25","unstructured":"CMSC. CMSC best practices for the use of serum neurofilament (sNfL) in MS management. 2024; Available from: https:\/\/mscare.sharefile.com\/share\/view\/s60a6a95b73684d83873c6d9cab9d66b8."},{"issue":"10","key":"4547_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54(10):1655\u201361.","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"4547_CR27","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1177\/1352458518791518","volume":"24","author":"M Khalil","year":"2018","unstructured":"Khalil M. Are neurofilaments valuable biomarkers for long-term disease prognostication in MS? Mult Scler. 2018;24(10):1270\u20131.","journal-title":"Mult Scler"},{"issue":"5","key":"4547_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, et al. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol. 2024;20(5):269\u201387.","journal-title":"Nat Rev Neurol"},{"key":"4547_CR29","unstructured":"Cross AH. B-Cell depletion and efficacy outcomes of ofatumumab are consistent across different body mass index categories: insights from ASCLEPIOS I and II trials. P098. Poster presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. 2024."},{"issue":"13","key":"4547_CR30","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/13524585241277044","volume":"30","author":"ZY van Lierop","year":"2024","unstructured":"van Lierop ZY, Wessels MH, Lekranty WM, Moraal B, Hof SN, Hogenboom L, et al. Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic. Mult Scler. 2024;30(13):1620\u20139.","journal-title":"Mult Scler"},{"key":"4547_CR31","doi-asserted-by":"crossref","unstructured":"Akguen K. NeofiLos \u2013 sNfL in daily clinical routine. P015. Poster presented at the 77th Annual Meeting of American Academy of Neurology (AAN). 2025.","DOI":"10.1212\/WNL.0000000000211726"},{"key":"4547_CR32","doi-asserted-by":"publisher","first-page":"654942","DOI":"10.3389\/fnins.2021.654942","volume":"15","author":"S Thebault","year":"2021","unstructured":"Thebault S, Booth RA, Rush CA, MacLean H, Freedman MS. Serum neurofilament light chain measurement in MS: hurdles to clinical translation. Front Neurosci. 2021;15:654942.","journal-title":"Front Neurosci"},{"key":"4547_CR33","unstructured":"Lorscheider J, Benkert P, Yaldizli \u00d6, Disanto G, Oechtering J, Wuerfel J et al. Serum neurofilament light chain captures and predicts confirmed progression independent of relapses (PIRA) in multiple sclerosis. P0154. Presented at the MS Virtual conference. 2020."},{"key":"4547_CR34","doi-asserted-by":"publisher","first-page":"103590","DOI":"10.1016\/j.ebiom.2021.103590","volume":"72","author":"T Uphaus","year":"2021","unstructured":"Uphaus T, Steffen F, Muthuraman M, Ripfel N, Fleischer V, Groppa S, et al. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study. EBioMedicine. 2021;72:103590.","journal-title":"EBioMedicine"},{"issue":"6","key":"4547_CR35","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/acn3.51060","volume":"7","author":"M Rosso","year":"2020","unstructured":"Rosso M, Gonzalez CT, Healy BC, Saxena S, Paul A, Bjornevik K, et al. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020;7(6):945\u201355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"4547_CR36","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1111\/ene.15419","volume":"29","author":"A Adams","year":"2022","unstructured":"Adams A, Tilden W, Bestwick J, Holden D, Bianchi L, Smets I, et al. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis. Eur J Neurol. 2022;29(9):2754\u201360.","journal-title":"Eur J Neurol"},{"issue":"9","key":"4547_CR37","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","volume":"63","author":"N Norgren","year":"2004","unstructured":"Norgren N, Sundstr\u00f6m P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004;63(9):1586\u201390.","journal-title":"Neurology"},{"issue":"6","key":"4547_CR38","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/13524585211039104","volume":"28","author":"I Rosenstein","year":"2022","unstructured":"Rosenstein I, Axelsson M, Novakova L, Blennow K, Zetterberg H, Lycke J. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Mult Scler. 2022;28(6):872\u201384.","journal-title":"Mult Scler"},{"issue":"23","key":"4547_CR39","doi-asserted-by":"publisher","first-page":"e2457","DOI":"10.1212\/WNL.0000000000009571","volume":"94","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Stridh P, Khademi M, Leppert D, Barro C, Michalak Z, et al. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology. 2020;94(23):e2457\u201367.","journal-title":"Neurology"},{"key":"4547_CR40","doi-asserted-by":"publisher","first-page":"102807","DOI":"10.1016\/j.ebiom.2020.102807","volume":"56","author":"S Bittner","year":"2020","unstructured":"Bittner S, Steffen F, Uphaus T, Muthuraman M, Fleischer V, Salmen A, et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine. 2020;56:102807.","journal-title":"EBioMedicine"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04547-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:05:06Z","timestamp":1769558706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04547-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4547"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04547-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"From a legal or regulatory point of view, there is no obligation in the UK to submit this type of survey to an ethics committee. The questionnaire of the survey was subject to review and approval by the UK Novartis \u2018Ethics, Risks & Compliance\u2019 department. The Novartis \u2018Ethics, Risks & Compliance\u2019 departments of the UK approved the conduct of the survey in the respective countries. All the participated healthcare professionals provided written informed consent to participate in the survey, to the collection and processing of their personal data and to the following agreement: \u2018Novartis is a member of the Association of the British Pharmaceutical Industry (\u201cABPI\u201d) and is required to apply with the Code of Practice (\u201cCode\u201d), as amended from time to time. Whenever you write or speak in public about a matter that is the subject of this agreement or any other issue relating to Novartis, you shall disclose the following: (i) Novartis has retained you for professional services in relation to this study; and (ii) any other relationships that Novartis has with you which a reasonable and ethical person would expect to be disclosed. We would like to assure you that we also act in accordance with the ESOMAR, EphMRA, BHBIA and PBIRG\/Insights Association codes of conduct regarding anonymity and confidentiality. By participating in the study, you acknowledge and accept that your participation is voluntary and is not based on an inducement to prescribe, supply, administer, recommend, buy or sell any Novartis medicine. You have the right to refuse to answer a question or completely withdraw from the research at any time.\u2019 There was no inclusion of patient data at any point in time throughout the survey. Therefore, no written patient informed consent is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SG has received honoraria from Biogen, Idec, Janssen, Merck, MS Academy, Novartis, Roche, Sanofi Genzyme and Teva for speaker engagement and travel support. She has also received research support in the form of grants from Merck, NHS Digital, NIHR, Sanofi Genzyme, Takeda and the UK MS Society.PG has received research funding, speaker honoraria, travel and\/or educational support from Sanofi Genzyme, Novartis, Biogen, Merck Serono, Bristol Myers Squibb and Roche Pharmaceuticals.TA has received honoraria or consulting fees for participating in advisory boards related to trial steering committees and data and safety monitoring committees, speaker fees & research grants Janssen, Merck, Novartis, Roche and Sanofi-Genzyme. She is partially funded by the NIHR SCPRA fellowship.NRK and JM are employees of Novartis Pharmaceuticals UK Ltd. MR was an employee of Novartis Pharmaceuticals UK Ltd during the study period.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}